ORICNasdaqPharmaceutical PreparationsFiscal year ends December 31
Oric Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$12.72+0.37 (+3.00%)
Close on Oct 19, 2026
- Market cap
- $1.37B
- P/E (TTM)
- –
- Dividend yield
- –
Oric Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Oric Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $1.32B | $166.30M |
| Enterprise Value | $1.05B | $88.19M |
| PB Ratio | 3.46 | 2.03 |
| P/TBV Ratio | 3.46 | 2.29 |
Income (trailing twelve months)
| Measure | Oric Pharmaceuticals | Industry median |
|---|---|---|
| Operating Income | -$156.14M | -$21.40M |
| Net Income | -$140.35M | -$22.46M |
| EBITDA | -$156.14M | -$16.91M |
| EPS (Diluted) | -$1.35 | -$0.83 |
Returns
| Measure | Oric Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -39.8% | -53.2% |
| Return on Assets (ROA) | -37.4% | -40.9% |
| Return on Invested Capital (ROIC) | -156.2% | -32.4% |
| Return on Capital Employed (ROCE) | -40.7% | -38.1% |
Balance sheet
| Measure | Oric Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $264.76M | $61.43M |
| Net Cash (Debt) | $264.76M | $15.35M |
| Net Cash Per Share | $2.55 | $0.66 |
| Equity (Book Value) | $381.26M | $49.09M |
| Book Value Per Share | $3.68 | $1.37 |
| Tangible Book Value | $381.26M | $23.52M |
| Working Capital | $252.94M | $76.81M |
Financial position
| Measure | Oric Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 13.19 | 3.34 |
| Quick Ratio | 12.76 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Oric Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$111.64M | -$12.35M |
| Capital Expenditures | -$620.00K | -$1.08M |
| Free Cash Flow | -$112.26M | -$20.22M |
| FCF Per Share | -$1.08 | -$0.42 |
Efficiency
| Measure | Oric Pharmaceuticals | Industry median |
|---|---|---|
| Profits Per Employee | -$1.35M | -$703.34K |
| Employee Count | 104 | 74 |
Dividends and yields
| Measure | Oric Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -10.6% | -23.3% |
| FCF Yield | -8.51% | -8.72% |
| Buyback Yield | -13.0% | -0.59% |
| Shareholder Yield | -13.0% | 0.00% |
Shares
| Measure | Oric Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 103,653,000 | 58,127,000 |
| Shares Change (YoY) | 43.0% | 10.9% |
| Shares Change (QoQ) | 0.14% | 0.54% |
| Float | 97,947,000 | 49,136,700 |
| Shares Held by Insiders | 5.50% | 11.6% |
| Shares Held by Institutions | 119.2% | 59.4% |
Scores
| Measure | Oric Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 30.58 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Oric Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.